Report Detail
Global Therapeutic Monoclonal Antibodies Market 2023 by Company, Regions, Type and Application, Forecast to 2029
- RnM4567001 |
- 24 November, 2023 |
- Global |
- 129 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Therapeutic Monoclonal Antibodies market size was valued at USD 167110 million in 2022 and is forecast to a readjusted size of USD 336740 million by 2029 with a CAGR of 10.5% during review period.
Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.
The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.
The Global Info Research report includes an overview of the development of the Therapeutic Monoclonal Antibodies industry chain, the market status of Immune Diseases (Mouse-derived Antibodies, Chimeric Antibodies), Cancer (Mouse-derived Antibodies, Chimeric Antibodies), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Therapeutic Monoclonal Antibodies.
Regionally, the report analyzes the Therapeutic Monoclonal Antibodies markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Therapeutic Monoclonal Antibodies market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Therapeutic Monoclonal Antibodies market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Therapeutic Monoclonal Antibodies industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Mouse-derived Antibodies, Chimeric Antibodies).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Therapeutic Monoclonal Antibodies market.
Regional Analysis: The report involves examining the Therapeutic Monoclonal Antibodies market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Therapeutic Monoclonal Antibodies market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Therapeutic Monoclonal Antibodies:
Company Analysis: Report covers individual Therapeutic Monoclonal Antibodies players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Therapeutic Monoclonal Antibodies This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Immune Diseases, Cancer).
Technology Analysis: Report covers specific technologies relevant to Therapeutic Monoclonal Antibodies. It assesses the current state, advancements, and potential future developments in Therapeutic Monoclonal Antibodies areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Therapeutic Monoclonal Antibodies market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Therapeutic Monoclonal Antibodies market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Mouse-derived Antibodies
Chimeric Antibodies
Humanized Antibodies
Market segment by Application
Immune Diseases
Cancer
Other
Market segment by players, this report covers
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
Regeneron
Innovent
Hengrui Medicine
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Therapeutic Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Therapeutic Monoclonal Antibodies, with revenue, gross margin and global market share of Therapeutic Monoclonal Antibodies from 2018 to 2023.
Chapter 3, the Therapeutic Monoclonal Antibodies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Therapeutic Monoclonal Antibodies market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Therapeutic Monoclonal Antibodies.
Chapter 13, to describe Therapeutic Monoclonal Antibodies research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope of Therapeutic Monoclonal Antibodies
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Therapeutic Monoclonal Antibodies by Type
- 1.3.1 Overview: Global Therapeutic Monoclonal Antibodies Market Size by Type: 2018 Versus 2022 Versus 2029
- 1.3.2 Global Therapeutic Monoclonal Antibodies Consumption Value Market Share by Type in 2022
- 1.3.3 Mouse-derived Antibodies
- 1.3.4 Chimeric Antibodies
- 1.3.5 Humanized Antibodies
- 1.4 Global Therapeutic Monoclonal Antibodies Market by Application
- 1.4.1 Overview: Global Therapeutic Monoclonal Antibodies Market Size by Application: 2018 Versus 2022 Versus 2029
- 1.4.2 Immune Diseases
- 1.4.3 Cancer
- 1.4.4 Other
- 1.5 Global Therapeutic Monoclonal Antibodies Market Size & Forecast
- 1.6 Global Therapeutic Monoclonal Antibodies Market Size and Forecast by Region
- 1.6.1 Global Therapeutic Monoclonal Antibodies Market Size by Region: 2018 VS 2022 VS 2029
- 1.6.2 Global Therapeutic Monoclonal Antibodies Market Size by Region, (2018-2029)
- 1.6.3 North America Therapeutic Monoclonal Antibodies Market Size and Prospect (2018-2029)
- 1.6.4 Europe Therapeutic Monoclonal Antibodies Market Size and Prospect (2018-2029)
- 1.6.5 Asia-Pacific Therapeutic Monoclonal Antibodies Market Size and Prospect (2018-2029)
- 1.6.6 South America Therapeutic Monoclonal Antibodies Market Size and Prospect (2018-2029)
- 1.6.7 Middle East and Africa Therapeutic Monoclonal Antibodies Market Size and Prospect (2018-2029)
2 Company Profiles
- 2.1 AbbVie
- 2.1.1 AbbVie Details
- 2.1.2 AbbVie Major Business
- 2.1.3 AbbVie Therapeutic Monoclonal Antibodies Product and Solutions
- 2.1.4 AbbVie Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.1.5 AbbVie Recent Developments and Future Plans
- 2.2 Johnson & Johnson
- 2.2.1 Johnson & Johnson Details
- 2.2.2 Johnson & Johnson Major Business
- 2.2.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Product and Solutions
- 2.2.4 Johnson & Johnson Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.2.5 Johnson & Johnson Recent Developments and Future Plans
- 2.3 Novartis
- 2.3.1 Novartis Details
- 2.3.2 Novartis Major Business
- 2.3.3 Novartis Therapeutic Monoclonal Antibodies Product and Solutions
- 2.3.4 Novartis Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.3.5 Novartis Recent Developments and Future Plans
- 2.4 Gilead Sciences
- 2.4.1 Gilead Sciences Details
- 2.4.2 Gilead Sciences Major Business
- 2.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Product and Solutions
- 2.4.4 Gilead Sciences Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.4.5 Gilead Sciences Recent Developments and Future Plans
- 2.5 Roche
- 2.5.1 Roche Details
- 2.5.2 Roche Major Business
- 2.5.3 Roche Therapeutic Monoclonal Antibodies Product and Solutions
- 2.5.4 Roche Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.5.5 Roche Recent Developments and Future Plans
- 2.6 Bristol-Myers Squibb
- 2.6.1 Bristol-Myers Squibb Details
- 2.6.2 Bristol-Myers Squibb Major Business
- 2.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Product and Solutions
- 2.6.4 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.6.5 Bristol-Myers Squibb Recent Developments and Future Plans
- 2.7 Amgen
- 2.7.1 Amgen Details
- 2.7.2 Amgen Major Business
- 2.7.3 Amgen Therapeutic Monoclonal Antibodies Product and Solutions
- 2.7.4 Amgen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.7.5 Amgen Recent Developments and Future Plans
- 2.8 AstraZeneca
- 2.8.1 AstraZeneca Details
- 2.8.2 AstraZeneca Major Business
- 2.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Product and Solutions
- 2.8.4 AstraZeneca Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.8.5 AstraZeneca Recent Developments and Future Plans
- 2.9 Merck & Co
- 2.9.1 Merck & Co Details
- 2.9.2 Merck & Co Major Business
- 2.9.3 Merck & Co Therapeutic Monoclonal Antibodies Product and Solutions
- 2.9.4 Merck & Co Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.9.5 Merck & Co Recent Developments and Future Plans
- 2.10 Takeda
- 2.10.1 Takeda Details
- 2.10.2 Takeda Major Business
- 2.10.3 Takeda Therapeutic Monoclonal Antibodies Product and Solutions
- 2.10.4 Takeda Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.10.5 Takeda Recent Developments and Future Plans
- 2.11 Merck KGaA
- 2.11.1 Merck KGaA Details
- 2.11.2 Merck KGaA Major Business
- 2.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Product and Solutions
- 2.11.4 Merck KGaA Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.11.5 Merck KGaA Recent Developments and Future Plans
- 2.12 Seagen
- 2.12.1 Seagen Details
- 2.12.2 Seagen Major Business
- 2.12.3 Seagen Therapeutic Monoclonal Antibodies Product and Solutions
- 2.12.4 Seagen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.12.5 Seagen Recent Developments and Future Plans
- 2.13 Eli Lilly
- 2.13.1 Eli Lilly Details
- 2.13.2 Eli Lilly Major Business
- 2.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Product and Solutions
- 2.13.4 Eli Lilly Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.13.5 Eli Lilly Recent Developments and Future Plans
- 2.14 Ono Pharmaceutical
- 2.14.1 Ono Pharmaceutical Details
- 2.14.2 Ono Pharmaceutical Major Business
- 2.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Product and Solutions
- 2.14.4 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.14.5 Ono Pharmaceutical Recent Developments and Future Plans
- 2.15 Pfizer
- 2.15.1 Pfizer Details
- 2.15.2 Pfizer Major Business
- 2.15.3 Pfizer Therapeutic Monoclonal Antibodies Product and Solutions
- 2.15.4 Pfizer Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.15.5 Pfizer Recent Developments and Future Plans
- 2.16 Regeneron
- 2.16.1 Regeneron Details
- 2.16.2 Regeneron Major Business
- 2.16.3 Regeneron Therapeutic Monoclonal Antibodies Product and Solutions
- 2.16.4 Regeneron Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.16.5 Regeneron Recent Developments and Future Plans
- 2.17 Innovent
- 2.17.1 Innovent Details
- 2.17.2 Innovent Major Business
- 2.17.3 Innovent Therapeutic Monoclonal Antibodies Product and Solutions
- 2.17.4 Innovent Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.17.5 Innovent Recent Developments and Future Plans
- 2.18 Hengrui Medicine
- 2.18.1 Hengrui Medicine Details
- 2.18.2 Hengrui Medicine Major Business
- 2.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Product and Solutions
- 2.18.4 Hengrui Medicine Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
- 2.18.5 Hengrui Medicine Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Therapeutic Monoclonal Antibodies Revenue and Share by Players (2018-2023)
- 3.2 Market Share Analysis (2022)
- 3.2.1 Market Share of Therapeutic Monoclonal Antibodies by Company Revenue
- 3.2.2 Top 3 Therapeutic Monoclonal Antibodies Players Market Share in 2022
- 3.2.3 Top 6 Therapeutic Monoclonal Antibodies Players Market Share in 2022
- 3.3 Therapeutic Monoclonal Antibodies Market: Overall Company Footprint Analysis
- 3.3.1 Therapeutic Monoclonal Antibodies Market: Region Footprint
- 3.3.2 Therapeutic Monoclonal Antibodies Market: Company Product Type Footprint
- 3.3.3 Therapeutic Monoclonal Antibodies Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Therapeutic Monoclonal Antibodies Consumption Value and Market Share by Type (2018-2023)
- 4.2 Global Therapeutic Monoclonal Antibodies Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
- 5.1 Global Therapeutic Monoclonal Antibodies Consumption Value Market Share by Application (2018-2023)
- 5.2 Global Therapeutic Monoclonal Antibodies Market Forecast by Application (2024-2029)
6 North America
- 6.1 North America Therapeutic Monoclonal Antibodies Consumption Value by Type (2018-2029)
- 6.2 North America Therapeutic Monoclonal Antibodies Consumption Value by Application (2018-2029)
- 6.3 North America Therapeutic Monoclonal Antibodies Market Size by Country
- 6.3.1 North America Therapeutic Monoclonal Antibodies Consumption Value by Country (2018-2029)
- 6.3.2 United States Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 6.3.3 Canada Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 6.3.4 Mexico Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
7 Europe
- 7.1 Europe Therapeutic Monoclonal Antibodies Consumption Value by Type (2018-2029)
- 7.2 Europe Therapeutic Monoclonal Antibodies Consumption Value by Application (2018-2029)
- 7.3 Europe Therapeutic Monoclonal Antibodies Market Size by Country
- 7.3.1 Europe Therapeutic Monoclonal Antibodies Consumption Value by Country (2018-2029)
- 7.3.2 Germany Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 7.3.3 France Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 7.3.4 United Kingdom Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 7.3.5 Russia Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 7.3.6 Italy Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
8 Asia-Pacific
- 8.1 Asia-Pacific Therapeutic Monoclonal Antibodies Consumption Value by Type (2018-2029)
- 8.2 Asia-Pacific Therapeutic Monoclonal Antibodies Consumption Value by Application (2018-2029)
- 8.3 Asia-Pacific Therapeutic Monoclonal Antibodies Market Size by Region
- 8.3.1 Asia-Pacific Therapeutic Monoclonal Antibodies Consumption Value by Region (2018-2029)
- 8.3.2 China Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 8.3.3 Japan Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 8.3.4 South Korea Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 8.3.5 India Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 8.3.6 Southeast Asia Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 8.3.7 Australia Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
9 South America
- 9.1 South America Therapeutic Monoclonal Antibodies Consumption Value by Type (2018-2029)
- 9.2 South America Therapeutic Monoclonal Antibodies Consumption Value by Application (2018-2029)
- 9.3 South America Therapeutic Monoclonal Antibodies Market Size by Country
- 9.3.1 South America Therapeutic Monoclonal Antibodies Consumption Value by Country (2018-2029)
- 9.3.2 Brazil Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 9.3.3 Argentina Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
10 Middle East & Africa
- 10.1 Middle East & Africa Therapeutic Monoclonal Antibodies Consumption Value by Type (2018-2029)
- 10.2 Middle East & Africa Therapeutic Monoclonal Antibodies Consumption Value by Application (2018-2029)
- 10.3 Middle East & Africa Therapeutic Monoclonal Antibodies Market Size by Country
- 10.3.1 Middle East & Africa Therapeutic Monoclonal Antibodies Consumption Value by Country (2018-2029)
- 10.3.2 Turkey Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 10.3.3 Saudi Arabia Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
- 10.3.4 UAE Therapeutic Monoclonal Antibodies Market Size and Forecast (2018-2029)
11 Market Dynamics
- 11.1 Therapeutic Monoclonal Antibodies Market Drivers
- 11.2 Therapeutic Monoclonal Antibodies Market Restraints
- 11.3 Therapeutic Monoclonal Antibodies Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Therapeutic Monoclonal Antibodies Industry Chain
- 12.2 Therapeutic Monoclonal Antibodies Upstream Analysis
- 12.3 Therapeutic Monoclonal Antibodies Midstream Analysis
- 12.4 Therapeutic Monoclonal Antibodies Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Therapeutic Monoclonal Antibodies. Industry analysis & Market Report on Therapeutic Monoclonal Antibodies is a syndicated market report, published as Global Therapeutic Monoclonal Antibodies Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Therapeutic Monoclonal Antibodies market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
